Qualifications and training of adult stem cell donor recruiters: Recommendations by the World Marrow Donor Association

摘要

Allogeneic hematopoietic SCT (HSCT) remains the only curative but highly successful treatment for sickle cell disease.1 HSCT may be an acceptable treatment for patients with severe systemic lupus erythematosus (SLE).2 We report our experience of matched sibling HSCT in an 11-year-old girl with sickle cell disease complicated by SLE. The post transplant course was complicated by posterior leukoencephalopathy syndrome with status epilepticus secondary to cyclosporine toxicity, gastroduodenitis probably due to mycophenolate mofetil treatment, and mild acute and chronic graft-versus-host disease (GVHD). To the best of our knowledge, this is the first successful HSCT of concurrent sickle cell disease and SLE.